Literature DB >> 20838990

Effects of thienopyridines and thienopyrimidinones on L-type calcium current in isolated cardiomyocytes.

Brigitte Pelzmann1, Klaus Zorn-Pauly, Seth Hallström, Heinrich Mächler, Andrzej Jakubowski, Petra Lang, Bernd Koidl.   

Abstract

Thienopyridines (ticlopidine, clopidogrel) are frequently used drugs in antiplatelet therapy and have been shown to exert a more pronounced negative inotropic effect than thienopyrimidinones. We hypothesized that these differences are due to a differential impact of thienopyridines and thienopyrimidinones on L-type calcium current at the single-cell level. The effects of thienopyridines and thienopyrimidinones were studied on L-type calcium current and action potential parameters with the whole-cell patch-clamp technique in isolated myocytes from guinea pig ventricle and human atrial appendage. Ticlopidine showed the greatest impact on the L-type calcium current in guinea pig myocytes. It significantly reduced L-type calcium current density as well as shifted half maximal inactivation potential to more negative potentials compared to clopidogrel (at 30 μmol/L) and to all thienopyrimidinones (30 and 100 μmol/L). Clopidogrel significantly reduced the L-type calcium current density as well as shifted the half maximal inactivation potential to more negative potentials compared to all thienopyrimidinones at 100 μmol/L only. In contrast, thienopyrimidinones did not affect L-type calcium current properties. The significant different effects of thienopyridines and thienopyrimidinones could also be demonstrated in human atrial myocytes. The more pronounced negative inotropic effect of thienopyridines is well explained by our results demonstrating a differential impairment of L-type calcium current by thienopyridines and thienopyrimidinones. L-type calcium current impairment by thienopyridines may be of special relevance for patients with cardiac diseases characterized by ionic remodelling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838990     DOI: 10.1007/s00210-010-0557-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Effects of K+ channel openers on I K(ATP) of human atrial myocytes at physiological temperatures.

Authors:  B Pelzmann; P Schaffer; E Bernhart; P Lang; H Mächler; B Rigler; B Koidl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-02       Impact factor: 3.000

2.  Mathematical model of an adult human atrial cell: the role of K+ currents in repolarization.

Authors:  A Nygren; C Fiset; L Firek; J W Clark; D S Lindblad; R B Clark; W R Giles
Journal:  Circ Res       Date:  1998 Jan 9-23       Impact factor: 17.367

3.  Ionic mechanisms of electrical remodeling in human atrial fibrillation.

Authors:  R F Bosch; X Zeng; J B Grammer; K Popovic; C Mewis; V Kühlkamp
Journal:  Cardiovasc Res       Date:  1999-10       Impact factor: 10.787

4.  Oxidized LDL induces ventricular myocyte damage and abnormal electrical activity--role of lipid hydroperoxides.

Authors:  Klaus Zorn-Pauly; Peter Schaffer; Brigitte Pelzmann; Eva Bernhart; Guofeng Wei; Petra Lang; Gerhard Ledinski; Joachim Greilberger; Bernd Koidl; Günther Jürgens
Journal:  Cardiovasc Res       Date:  2005-01-08       Impact factor: 10.787

Review 5.  Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.

Authors:  Pierre Savi; Jean-Marc Herbert
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

6.  Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart.

Authors:  A Jakubowski; S Chlopicki; R Olszanecki; J Jawien; M Lomnicka; J P Dupin; R J Gryglewski
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-02       Impact factor: 4.006

Review 7.  [Clopidogrel--clinical use and potential therapeutic problems].

Authors:  Andreas Schäfer; Johann Bauersachs; Martin Eigenthaler
Journal:  Herz       Date:  2008-06       Impact factor: 1.443

8.  Synthesis and thrombolytic activity of new thienopyrimidinone derivatives.

Authors:  J P Dupin; R J Gryglewski; D Gravier; G Hou; F Casadebaig; J Swies; S Chlopicki
Journal:  J Physiol Pharmacol       Date:  2002-12       Impact factor: 3.011

Review 9.  Antiplatelet therapy: in search of the 'magic bullet'.

Authors:  Shaun P Jackson; Simone M Schoenwaelder
Journal:  Nat Rev Drug Discov       Date:  2003-10       Impact factor: 84.694

Review 10.  Future innovations in anti-platelet therapies.

Authors:  N E Barrett; L Holbrook; S Jones; W J Kaiser; L A Moraes; R Rana; T Sage; R G Stanley; K L Tucker; B Wright; J M Gibbins
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

View more
  1 in total

Review 1.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.